Results 201 to 210 of about 3,273,209 (295)

A Dual-Purpose Approach for an Anti-Emetic NK1R Antagonist as a Chemosensitizer and Cardioprotectant in a Preclinical Model of Triple-Negative Breast Cancer. [PDF]

Int J Mol Sci
Muñoz M, Coveñas R, Zuberi Y, Italia Z, Hoang T, Italia Z, Robinson P.   +6 more
europepmc   +1 more source

GLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection. [PDF]

Front Endocrinol (Lausanne)
Wang X, Qi M, Yang L, Yang L, Wang X, Zhang F, Cui Y, Wang D, Wang Y, Lv W.   +9 more
europepmc   +1 more source

The Application of the Criteria of the Just War Theories in the Resolution of Medical-Ethical Dilemmas at the Bedside [PDF]

, 1995
Baker, Anne B.
core   +1 more source

Role of Na⁺-K⁺ ATPase Alterations in the Development of Heart Failure. [PDF]

Int J Mol Sci
Dhalla NS, Elimban V, Adameova AD.
europepmc   +1 more source

Cardioprotective potential of shikonin in cardiac hypertrophy is mediated through PKM2/c-Myc/PTBP1/HIF-1α signaling pathway.

Indian J Pharmacol
Rihan M, Sharma SS.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The therapeutic potential of novel cardiotonic agents

Expert Opinion on Investigational Drugs, 2003
During the course of treatment of heart failure patients, cardiotonic agents are inevitable for improvement of myocardial dysfunction. Clinically available agents, such as beta-adrenoceptor agonists and selective phosphodiesterase 3 inhibitors, act mainly via cyclic AMP/protein kinase A-mediated facilitation of Ca(2+) mobilisation (upstream mechanism).
M. Endoh
openaire   +3 more sources

Quantitative structure - activity relationships of cardiotonic agents

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 2000
Quantitative structure-activity relationships (QSARs) of different cardiotonic agents are presented. A critical analysis of all QSARs provides a very vivid picture of the mechanisms of varying cardiotonic agents. The cardiotonics can be broadly put into 2 categories: cardiac glycosides and nonglycoside cardiotonics, which include phosphodiesterase of ...
S. Gupta
openaire   +3 more sources

Cardiotonic Agents

2016
I. Mohanty
openaire   +2 more sources

Cardiotonic agents in the management of chronic cardiac failure

American Heart Journal, 1982
Heart failure is a syndrome with distinct clinical signs and symptoms. The severity of cardiac failure and a deterioration in functional capacity can be determined by a progressive exercise test and by the noninvasive determination of maximum oxygen uptake.
K T, Weber, V, Andrews, J S, Janicki
openaire   +3 more sources

New cardiotonic agents: A search for digitalis substitute

Life Sciences, 1978
A E, Farah, A A, Alousi
openaire   +3 more sources